IDH2 and glioblastoma: Understanding the frequency and association of TERTp mutations is important for molecular classification and for potential targeted therapies, as unveiled for the prognostic interaction of TERTp mutations with MGMT promoter methylation in IDH-wildtype glioblastoma patients, who presented a better outcome when treated with temozolomide [23,24].